Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Phase 1 Completed 33 enrolled Escient Pharmaceuticals, Inc

NaSingle-groupOpen-labelTreatment

Summary

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.

Timeline

Start: 2023-08-30
Primary completion: 2024-10-22
Completion: 2024-10-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EP262	Unknown	150 mg	Oral

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Summary

Timeline

Drugs

Indications